{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:21:21Z","timestamp":1790623281609,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008321","name":"Pennsylvania State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.josat.2023.209270","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T06:03:54Z","timestamp":1702533834000},"page":"209270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["\u201cI think we're getting better but we're still not there\u201d: Provider-based stigma and perceived barriers to care for people who use opioids (PWUO)"],"prefix":"10.1016","volume":"159","author":[{"given":"Katherine","family":"McLean","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Kruis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.josat.2023.209270_bb0005","author":"Administration for Community Living"},{"key":"10.1016\/j.josat.2023.209270_bb0010","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jsat.2015.10.003","article-title":"Extended-release naltrexone: A qualitative analysis of barriers to routine use","volume":"62","author":"Alanis-Hirsch","year":"2016","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.209270_bb0015","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jsat.2016.08.002","article-title":"Non-prescribed buprenorphine in New York City: Motivations for use, practices of diversion, and experiences of stigma","volume":"70","author":"Allen","year":"2016","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.209270_bb0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugpo.2017.11.021","article-title":"A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices","volume":"54","author":"Andraka-Christou","year":"2018","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.josat.2023.209270_bb0025","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jsat.2019.04.008","article-title":"Experiences of care among individuals with opioid use disorder-associated endocarditis and their healthcare providers: Results from a qualitative study","volume":"102","author":"Bearnot","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"4","key":"10.1016\/j.josat.2023.209270_bb0030","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1001\/jamapsychiatry.2020.3177","article-title":"Opportunities for research on the treatment of substance use disorders in the context of COVID-19","volume":"78","author":"Blanco","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.josat.2023.209270_bb0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/08897077.2015.1080208","article-title":"Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013","volume":"37","author":"Burns","year":"2016","journal-title":"Substance Abuse"},{"key":"10.1016\/j.josat.2023.209270_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108543","article-title":"The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth","volume":"133","author":"Cales","year":"2022","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.209270_bb0045","series-title":"Impact of COVID-19 on state and federal prisons, March 2020\u2013February 2021 (special report)","author":"Carson","year":"2022"},{"key":"10.1016\/j.josat.2023.209270_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.rcsop.2021.100029","article-title":"A systematic literature review of patient perspectives of barriers and facilitators to access, adherence, stigma, and persistence to treatment for substance use disorder","volume":"2","author":"Cernasev","year":"2021","journal-title":"Exploratory Research in Clinical and Social Pharmacy"},{"key":"10.1016\/j.josat.2023.209270_bb0055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.drugalcdep.2018.04.012","article-title":"Exploring opioid use disorder, its impact, and treatment among individuals experiencing homelessness as part of a family","volume":"188","author":"Chatterjee","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2023.209270_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108146","article-title":"A systematic review of patients\u2019 and providers\u2019 perspectives of medications for treatment of opioid use disorder","volume":"119","author":"Cioe","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"10","key":"10.1016\/j.josat.2023.209270_bb0065","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2105\/AJPH.2018.304666","article-title":"The first comprehensive program for opioid use disorder in a US statewide correctional system","volume":"108","author":"Clarke","year":"2018","journal-title":"American Journal of Public Health"},{"issue":"5","key":"10.1016\/j.josat.2023.209270_bb0070","first-page":"336","article-title":"Attending physicians\u2019 and residents\u2019 attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital","volume":"38","author":"Cunningham","year":"2006","journal-title":"Family Medicine"},{"issue":"1","key":"10.1016\/j.josat.2023.209270_bb0075","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jsat.2014.07.015","article-title":"Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants","volume":"48","author":"Fox","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"5","key":"10.1016\/j.josat.2023.209270_bb0080","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jsat.2012.10.005","article-title":"Forced withdrawal from methadone maintenance therapy in criminal justice settings: A critical treatment barrier in the United States","volume":"44","author":"Fu","year":"2013","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.josat.2023.209270_bb0085","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/10550887.2012.759860","article-title":"Suboxone misuse along the opiate maintenance treatment pathway","volume":"32","author":"Furst","year":"2013","journal-title":"Journal of Addictive Diseases"},{"issue":"12","key":"10.1016\/j.josat.2023.209270_bb0090","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1016\/j.addbeh.2013.08.008","article-title":"Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland","volume":"38","author":"Genberg","year":"2013","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.josat.2023.209270_bb1000","series-title":"Discovery of Grounded Theory: Strategies for Qualitative Research (eBook)","author":"Glaser","year":"2017"},{"key":"10.1016\/j.josat.2023.209270_bb0095","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13722-019-0139-3","article-title":"Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence","volume":"14","author":"Godersky","year":"2019","journal-title":"Addiction Science & Clinical Practice"},{"key":"10.1016\/j.josat.2023.209270_bb0100","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1037\/a0022776","article-title":"Facilitators and barriers in implementing buprenorphine in the veterans health administration","volume":"25","author":"Gordon","year":"2011","journal-title":"Psychology of Addictive Behaviors"},{"issue":"1","key":"10.1016\/j.josat.2023.209270_bb0105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13011-020-00312-3","article-title":"A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder","volume":"15","author":"Haffajee","year":"2020","journal-title":"Substance Abuse Treatment, Prevention, and Policy"},{"issue":"2","key":"10.1016\/j.josat.2023.209270_bb0110","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/10826084.2017.1385633","article-title":"At the expense of a life: Race, class, and the meaning of buprenorphine in pharmaceuticalized \u201ccare.\u201d","volume":"53","author":"Hatcher","year":"2018","journal-title":"Substance Use & Misuse"},{"issue":"1","key":"10.1016\/j.josat.2023.209270_bb0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13011-016-0085-y","article-title":"Systemic and individual factors in the buprenorphine treatment-seeking process: A qualitative study","volume":"12","author":"Hewell","year":"2017","journal-title":"Substance Abuse Treatment, Prevention, and Policy"},{"issue":"9","key":"10.1016\/j.josat.2023.209270_bb2000","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1177\/1049732305276687","article-title":"Three approaches to qualitative content analysis","volume":"15","author":"Hsieh","year":"2005","journal-title":"Qualitative Health Research"},{"issue":"1","key":"10.1016\/j.josat.2023.209270_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10550887.2014.975617","article-title":"Diversion of methadone and buprenorphine from opioid substitution treatment: Patients who regularly sell or share their medication","volume":"34","author":"Johnson","year":"2015","journal-title":"Journal of Addictive Diseases"},{"issue":"10","key":"10.1016\/j.josat.2023.209270_bb0125","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/jamapsychiatry.2022.2284","article-title":"Receipt of telehealth services, receipt and retention of medications for opioid use disorder, and medically treated overdose among medicare beneficiaries before and during the COVID-19 pandemic","volume":"79","author":"Jones","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.josat.2023.209270_bb0130","series-title":"Enforcing freedom: Drug courts, therapeutic communities, and the intimacies of the state","author":"Kaye","year":"2019"},{"issue":"2","key":"10.1016\/j.josat.2023.209270_bb0135","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.46971","article-title":"Effect of exposure to visual campaigns and narrative vignettes on addiction stigma among health care professionals: A randomized clinical trial","volume":"5","author":"Kennedy-Hendricks","year":"2022","journal-title":"JAMA Network Open"},{"issue":"11","key":"10.1016\/j.josat.2023.209270_bb0140","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1001\/jamapsychiatry.2020.1624","article-title":"Comparison of driving times to opioid treatment programs and pharmacies in the US","volume":"77","author":"Kleinman","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.josat.2023.209270_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108485","article-title":"Exploring first responders\u2019 perceptions of medication for addiction treatment: Does stigma influence attitudes?","volume":"131","author":"Kruis","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.209270_bb0150","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.drugpo.2019.06.019","article-title":"\u201cThey\u2019re making it so hard for people to get help:\u201d motivations for non-prescribed buprenorphine use in a time of treatment expansion","volume":"71","author":"McLean","year":"2019","journal-title":"International Journal of Drug Policy"},{"issue":"5","key":"10.1016\/j.josat.2023.209270_bb0155","doi-asserted-by":"crossref","first-page":"544","DOI":"10.5993\/AJHB.30.5.11","article-title":"Clinic-based treatment for opioid dependence: A qualitative inquiry","volume":"30","author":"McMurphy","year":"2006","journal-title":"American Journal of Health Behavior"},{"key":"10.1016\/j.josat.2023.209270_bb0160","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13011-015-0009-2","article-title":"Implementing buprenorphine in addiction treatment: Payer and provider perspectives in Ohio","volume":"10","author":"Molfenter","year":"2015","journal-title":"Substance Abuse Treatment, Prevention, and Policy"},{"key":"10.1016\/j.josat.2023.209270_bb0165","series-title":"Illness or deviance? Drug courts, drug treatment, and the ambiguity of addiction","author":"Murphy","year":"2015"},{"issue":"4","key":"10.1016\/j.josat.2023.209270_bb0170","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/0022042620921363","article-title":"Police officers\u2019 views of naloxone and drug treatment: Does greater overdose response lead to more negativity?","volume":"50","author":"Murphy","year":"2020","journal-title":"Journal of Drug Issues"},{"key":"10.1016\/j.josat.2023.209270_bb0175","series-title":"COVID-19 & substance use","author":"National Institute on Drug Abuse","year":"2023"},{"issue":"10","key":"10.1016\/j.josat.2023.209270_bb0180","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.37912","article-title":"Analysis of US county characteristics and clinicians with waivers to prescribe buprenorphine after changes in federal education requirements","volume":"5","author":"Nguyen","year":"2022","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2023.209270_bb0185","author":"Pennsylvania Department of Drug & Alcohol Programs"},{"issue":"1","key":"10.1016\/j.josat.2023.209270_bb0190","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.drugpo.2008.07.004","article-title":"Why don\u2019t out-of-treatment individuals enter methadone treatment programmes?","volume":"21","author":"Peterson","year":"2010","journal-title":"International Journal of Drug Policy"},{"issue":"9991","key":"10.1016\/j.josat.2023.209270_bb0195","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0140-6736(14)62338-2","article-title":"Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: A randomised, open-label trial","volume":"386","author":"Rich","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"6","key":"10.1016\/j.josat.2023.209270_bb0200","doi-asserted-by":"crossref","first-page":"407","DOI":"10.5055\/jom.2013.0183","article-title":"Awareness of, experience with, and attitudes towards buprenorphine among opioid users visiting a New York City syringe exchange program","volume":"9","author":"Shah","year":"2013","journal-title":"Journal of Opioid Management"},{"issue":"6","key":"10.1016\/j.josat.2023.209270_bb0205","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11920-017-0783-9","article-title":"Update on barriers to pharmacotherapy for opioid use disorders","volume":"19","author":"Sharma","year":"2017","journal-title":"Current Psychiatry Reports"},{"issue":"2","key":"10.1016\/j.josat.2023.209270_bb0210","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5055\/jom.2013.0152","article-title":"Consumer attitudes about opioid addiction treatment: A focus group study in New York City","volume":"9","author":"Sohler","year":"2013","journal-title":"Journal of Opioid Management"},{"key":"10.1016\/j.josat.2023.209270_bb0215","author":"Substance Abuse and Mental Health Services Administration"},{"key":"10.1016\/j.josat.2023.209270_bb0220","author":"Substance Abuse and Mental Health Services Administration"},{"issue":"6","key":"10.1016\/j.josat.2023.209270_bb0225","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1521-0391.2014.12143.x","article-title":"Preliminary survey of office-based opioid treatment practices and attitudes among psychiatrists never receiving buprenorphine training to those who received training during residency","volume":"23","author":"Suzuki","year":"2014","journal-title":"The American Journal on Addictions"},{"issue":"5","key":"10.1016\/j.josat.2023.209270_bb0230","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1080\/02791072.2014.921743","article-title":"Patient perspectives on buprenorphine\/naloxone: A qualitative study of retention during the starting treatment with agonist replacement therapies (START) study","volume":"46","author":"Teruya","year":"2014","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/j.josat.2023.209270_bb0235","author":"The Unified Judicial System of Pennsylvania"},{"key":"10.1016\/j.josat.2023.209270_bb0240","series-title":"Judging addicts: Drug courts and coercion in the justice system","author":"Tiger","year":"2013"},{"issue":"14","key":"10.1016\/j.josat.2023.209270_bb0245","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1080\/10826084.2019.1653324","article-title":"Patient barriers and facilitators to medications for opioid use disorder in primary care","volume":"54","author":"Tofighi","year":"2019","journal-title":"Substance Use & Misuse"},{"issue":"15","key":"10.1016\/j.josat.2023.209270_bb0250","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1001\/archinte.165.15.1769","article-title":"Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence","volume":"165","author":"Turner","year":"2005","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.josat.2023.209270_bb0255","author":"U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality"},{"issue":"4","key":"10.1016\/j.josat.2023.209270_bb0260","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/MLR.0000000000000703","article-title":"Impact of medicaid expansion on medicaid-covered utilization of buprenorphine for opioid use disorder treatment","volume":"55","author":"Wen","year":"2017","journal-title":"Medical Care"},{"issue":"5","key":"10.1016\/j.josat.2023.209270_bb0265","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/NNR.0000000000000298","article-title":"Opioid Initiation to Substance Use Treatment: \u201cThey Just Want to Feel Normal.\u201d","volume":"67","author":"Wilson","year":"2018","journal-title":"Nursing Research"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875923003223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875923003223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T12:46:49Z","timestamp":1728564409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875923003223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":55,"alternative-id":["S2949875923003223"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2023.209270","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cI think we're getting better but we're still not there\u201d: Provider-based stigma and perceived barriers to care for people who use opioids (PWUO)","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2023.209270","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"209270"}}